Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00611026 · ClinicalTrials.gov registry record · Phase 3
Clinical Trial to Evaluate the Efficacy and Safety of Fesoterodine in Comparison to Tolterodine Extended Release(ER)in Patients With Overactive Bladder.
A Phase 3 study, sponsored by Pfizer.
- Completed
- Registry status
- Phase 3
- Development phase
- 2,417
- Enrollment target
NCT00611026: Completed Phase 3 study, sponsored by Pfizer.
NCT00611026 is a Phase 3 study that has completed, run by Pfizer. The registered enrollment target is 2,417 participants, above the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (213% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00611026, a Phase 3 study, has completed, sponsored by Pfizer.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 2,417 participants
- Enrollment target
Study Summary
To evaluate the efficacy and safety of fesoterodine in comparison to tolterodine and placebo for overactive bladder
Primary Outcome
UUI per 24 hours: total number of micturitions with Urinary Sensation Scale (USS) of 5 divided by total number of diary days collected at visit. USS: 5-item scale to measure urinary urgency; range: 1 (no feeling of urgency) to 5 (unable to hold; leak urine).
Interventions
- DRUG Placebo
- DRUG Fesoterodine
- DRUG Tolterodine ER
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2,417 participants |
| Start Date | 2008-02 |
| Est. Completion | 2009-10 |
| Phase | Phase 3 |
What the finished NCT00611026 record still lists
NCT00611026 is an interventional study that assigns participants to a tested intervention. Its 2,417 participants enrollment target places it among the larger protocols in the corpus, above the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (213% higher).
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT00611026 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00611026 about?
NCT00611026 is a clinical study titled "Clinical Trial to Evaluate the Efficacy and Safety of Fesoterodine in Comparison to Tolterodine Extended Release(ER)in Patients With Overactive Bladder.". To evaluate the efficacy and safety of fesoterodine in comparison to tolterodine and placebo for overactive bladder
What is the current status of trial NCT00611026?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 2,417 participants. The study started on 2008-02. Estimated completion is 2009-10.
What interventions are being tested in trial NCT00611026?
The interventions under investigation include: Placebo (DRUG), Fesoterodine (DRUG), Tolterodine ER (DRUG).
Who is sponsoring clinical trial NCT00611026?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00611026's enrollment target sits among peer trials
2,417 89th of 2000 higher than 1,912 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05873387 · 2,420 participants
Development of an Algorithm to Detect Pulmonary Hypertension Using an Electronic Stethoscope
- NCT05345951 · 2,425 participants · NA
Project e-PBI+ - Parent Intervention to Reduce College Student Drinking and Cannabis Use
- NCT06676904 · 2,433 participants · NA
Neonatal Platelet Transfusion Threshold Trial
- NCT05185440 · 2,400 participants · NA
Reducing Alcohol Involved Sexual Violence in Higher Education
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia